C2N Diagnostics Secures $7 Million in Funding to Revolutionize Neurological Disorder Prevention and Diagnosis

C2N Diagnostics, a pioneering leader in the field of neurological health, is thrilled to announce the successful raising of $7 million in funding to advance its mission of bringing Clarity Through Innovation™ to patient care. With a dedicated focus on therapeutic discovery and the creation of innovative diagnostic solutions, C2N is committed to preventing the progression of neurological disorders through mechanism-based approaches. This significant financial boost will enable the company to enhance its flagship product, the PrecivityAD™ blood test, which is revolutionizing how Alzheimer’s disease is assessed. Recognized for its precision, the PrecivityAD™ test utilizes advanced mass spectrometry techniques to measure vital biomarkers in blood, aiding healthcare providers in evaluating the likelihood of brain amyloid plaques, a key indicator for Alzheimer’s disease. Although not a standalone diagnostic tool, the test, which received a Breakthrough Device Designation from the U.S. Food and Drug Administration in 2019 and has also achieved the CE Mark in the European Union, serves as an invaluable asset in the clinical diagnostic toolbox. The newly acquired funding will be channeled toward expanding the test’s accessibility and furthering research to support brain health monitoring, ultimately enriching the lives of countless patients and their families. With the vision of revolutionizing neurological care, C2N Diagnostics is poised to make a significant impact in the field, steering the course for improved diagnostics and therapeutic breakthroughs. For more information about their innovative solutions, please visit www.C2N.com.